Health

Novo Nordisk A/S: CagriSema 2.4 mg / 2.4 mg demonstrated 22.7% mean weight reduction in adults with overweight or obesity in REDEFINE 1, published in New England Journal of MedicineNovo Nordisk A/S: CagriSema 2.4 mg / 2.4 mg demonstrated 22.7% mean weight reduction in adults with overweight or obesity in REDEFINE 1, published in New England Journal of Medicine

Novo Nordisk A/S: CagriSema 2.4 mg / 2.4 mg demonstrated 22.7% mean weight reduction in adults with overweight or obesity in REDEFINE 1, published in New England Journal of Medicine

Data presented simultaneously at the American Diabetes Association’s® 85th Scientific Sessions, showed mean weight reduction in the highest range of…

3 days ago
Dr. Anosh Ahmed Advances Chicago Crypto Hub Project Amid National Pro-Crypto Policy ShiftDr. Anosh Ahmed Advances Chicago Crypto Hub Project Amid National Pro-Crypto Policy Shift

Dr. Anosh Ahmed Advances Chicago Crypto Hub Project Amid National Pro-Crypto Policy Shift

Dr. Anosh Ahmed converts vacant West Side warehouse into blockchain innovation hub, creating 250+ jobs and advancing tech-driven economic growth…

3 days ago
BioAge Labs to Present Preclinical Data on APJ Agonism for Diabetic Obesity and Heart Failure at the American Diabetes Association (ADA) 85th Scientific SessionsBioAge Labs to Present Preclinical Data on APJ Agonism for Diabetic Obesity and Heart Failure at the American Diabetes Association (ADA) 85th Scientific Sessions

BioAge Labs to Present Preclinical Data on APJ Agonism for Diabetic Obesity and Heart Failure at the American Diabetes Association (ADA) 85th Scientific Sessions

June 21, 2025 18:00 ET  | Source: BioAge Labs, Inc. Treatment with apelin receptor agonist enhanced glycemic control and demonstrated…

4 days ago
Abvance Therapeutics Announces Presentation of Human Clinical Data at the 85th Scientific Sessions of the American Diabetes AssociationAbvance Therapeutics Announces Presentation of Human Clinical Data at the 85th Scientific Sessions of the American Diabetes Association

Abvance Therapeutics Announces Presentation of Human Clinical Data at the 85th Scientific Sessions of the American Diabetes Association

CHICAGO, June 21, 2025 (GLOBE NEWSWIRE) -- Abvance Therapeutics, a biotechnology company developing next generation glucagon analogs and therapies to…

4 days ago
Nixol Capsules Launch in the UK: A Natural Path to Weight Management and Metabolic SupportNixol Capsules Launch in the UK: A Natural Path to Weight Management and Metabolic Support

Nixol Capsules Launch in the UK: A Natural Path to Weight Management and Metabolic Support

New York City, June 21, 2025 (GLOBE NEWSWIRE) -- Nixol, a plant-powered metabolic support supplement, is now available to individuals…

4 days ago
INVO Fertility Reminds Shareholders to Cast Their Vote for Upcoming Annual Meeting of Shareholders to be held on Wednesday, June 25, 2025 at 12:00 p.m. Eastern TimeINVO Fertility Reminds Shareholders to Cast Their Vote for Upcoming Annual Meeting of Shareholders to be held on Wednesday, June 25, 2025 at 12:00 p.m. Eastern Time

INVO Fertility Reminds Shareholders to Cast Their Vote for Upcoming Annual Meeting of Shareholders to be held on Wednesday, June 25, 2025 at 12:00 p.m. Eastern Time

SARASOTA, Fla., June 20, 2025 (GLOBE NEWSWIRE) -- INVO Fertility, Inc. (Nasdaq: IVF) (“INVO Fertility” or the “Company”), a healthcare…

6 days ago
EssilorLuxottica and Meta to launch Oakley Meta, creating a new category of Performance AI glasses for athletes and fans alikeEssilorLuxottica and Meta to launch Oakley Meta, creating a new category of Performance AI glasses for athletes and fans alike

EssilorLuxottica and Meta to launch Oakley Meta, creating a new category of Performance AI glasses for athletes and fans alike

EssilorLuxottica and Meta to launch Oakley Meta, creating a new category of Performance AI glasses for athletes and fans alike…

6 days ago
Actuate Therapeutics Reports Positive Biomarker and Machine Learning Data from Phase 2 Elraglusib Trial in First-Line Treatment of Metastatic Pancreatic Cancer at ASCOActuate Therapeutics Reports Positive Biomarker and Machine Learning Data from Phase 2 Elraglusib Trial in First-Line Treatment of Metastatic Pancreatic Cancer at ASCO

Actuate Therapeutics Reports Positive Biomarker and Machine Learning Data from Phase 2 Elraglusib Trial in First-Line Treatment of Metastatic Pancreatic Cancer at ASCO

Phase 2 highlights robust biomarker identification and survival correlations in first-line metastatic pancreatic cancer (mPDAC) treated with elraglusib June 20,…

6 days ago
Superlab Suisse to Open New Facility at Campus Biotech in Geneva in January 2026Superlab Suisse to Open New Facility at Campus Biotech in Geneva in January 2026

Superlab Suisse to Open New Facility at Campus Biotech in Geneva in January 2026

Zurich, June 19, 2025 (GLOBE NEWSWIRE) -- Superlab Suisse has announced the opening of its fourth Swiss laboratory facility at…

7 days ago
Kansas State University Veterinary Health Center Adopts Instinct EMR, Retires Legacy SystemKansas State University Veterinary Health Center Adopts Instinct EMR, Retires Legacy System

Kansas State University Veterinary Health Center Adopts Instinct EMR, Retires Legacy System

June 19, 2025 10:01 ET  | Source: Instinct Science PHILADELPHIA, June 19, 2025 (GLOBE NEWSWIRE) -- The Veterinary Health Center…

7 days ago